Autoimmune & ArthritisReview ArticlePaywall

PPH Kills a Woman Every 12 Minutes — New WHO Definition Aims to Change That

A major Lancet review reveals 27 million women suffer postpartum haemorrhage annually, costing $10.4B and claiming 43,000 lives — with most deaths preventable.

Monday, June 15, 2026 1 views
Published in Lancet
A healthcare worker in scrubs measuring blood loss into a calibrated collection drape in a hospital delivery room under bright surgical lighting

Summary

Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide, affecting an estimated 27 million women each year — 17 million after vaginal birth and 10 million after caesarean delivery. A new Lancet review from Oxford and WHO researchers documents the staggering scale: 43,000 deaths annually, serious complications including hysterectomy and organ failure, and a global economic burden of $10.4 billion. The WHO recently redefined PPH to prioritize earlier diagnosis, requiring objective blood loss measurement. The review identifies key missed opportunities: unmet contraception needs, untreated anaemia, unnecessary caesareans, and inconsistent use of proven uterotonic drugs. A global PPH Roadmap (2023–30) outlines a path forward.

Deep Dive Audio
0:00--:--

Detailed Summary

Postpartum haemorrhage remains the single largest cause of maternal mortality worldwide, yet the scale of the problem is often underappreciated. This comprehensive Lancet review from researchers at the University of Oxford and WHO provides the most current epidemiological picture, catalogues consequences, and maps the preventable gaps in care that cost tens of thousands of lives each year.

The numbers are stark. An estimated 27 million women experience PPH annually — roughly 12.6% of vaginal births and 30.9% of caesarean births globally. The death toll stands at approximately 43,000 per year, equating to one woman every 12 minutes. Beyond mortality, survivors face severe anaemia, emergency hysterectomy, multi-organ failure, and lasting psychological trauma. The global economic burden is estimated at $10.4 billion annually, with $6.8 billion falling on societies and $3.6 billion on health systems.

Common causes include uterine atony, genital tract trauma, retained placenta, abnormal placentation, and coagulopathy. Key risk factors are caesarean birth, multiple pregnancy, anaemia, elevated BMI, previous PPH, female genital mutilation, sepsis, pre-eclampsia, macrosomia, and inadequate antenatal care — many of which are modifiable.

A pivotal development reviewed here is the WHO's redefinition of PPH: objectively measured blood loss of at least 300 mL with an abnormal haemodynamic sign, or at least 500 mL regardless — whichever comes first. This shift prioritises early intervention before clinical deterioration. The review also highlights evidence-based interventions: combination uterotonic prophylaxis for high-risk women, objective blood loss measurement, and prompt deployment of treatment bundles.

The review's call to action centres on the PPH Roadmap (2023–30), a global framework addressing prevention through contraception access, risk mitigation, and standardised clinical protocols. Translating these recommendations into consistent practice, particularly in low-resource settings, remains the defining challenge.

Key Findings

  • PPH affects 27 million women annually — 12.6% of vaginal births and 30.9% of caesarean births worldwide.
  • 43,000 women die from PPH each year, one death every 12 minutes, making it the top cause of maternal mortality.
  • Global economic burden reaches $10.4 billion annually, with the majority falling on societies rather than health systems.
  • New WHO PPH definition requires objective blood loss measurement to enable earlier diagnosis and faster treatment.
  • Modifiable risks — anaemia, unnecessary caesareans, inadequate antenatal care — represent the largest missed prevention opportunities.

Methodology

This is a comprehensive review article published in The Lancet, drawing on pooled prevalence data, global burden estimates, and WHO guideline evidence synthesis. Quantitative estimates use 95% confidence intervals and credible intervals derived from systematic evidence review. The study integrates epidemiological data, economic modelling, and clinical guideline analysis from an international author team including WHO and University of Oxford researchers.

Study Limitations

This summary is based on the abstract only, as the full article is not open access; detailed methodology, subgroup analyses, and specific evidence gradings cannot be assessed. Pooled prevalence estimates carry wide credible intervals, reflecting heterogeneity across global settings. Economic burden estimates rely on modelling assumptions that may vary substantially by region and health system context.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.